CooperVision Highlights Research Advances at 2026 Netherlands Contact Lens Congress
- CooperVision will present significant research at the 2026 Netherlands Contact Lens Congress, enhancing vision care.
- Key studies include transitioning to dual-focus MiSight® lenses, showing early positive results in vision quality and comfort.
- Research on multifocal lenses highlights high satisfaction rates, emphasizing CooperVision's commitment to supporting presbyopic patients.
CooperVision to Showcase Innovative Research at NCC 2026
CooperVision is set to present a range of significant research findings at the upcoming 2026 Netherlands Contact Lens Congress (NCC) taking place on March 8-9 in Veldhoven, Netherlands. The company, recognized for its commitment to advancing vision care, continues to innovate in the design of contact lenses that address the evolving vision needs throughout various life stages, according to Marcella McParland, Senior Director of Professional Affairs for Europe, the Middle East, and Africa. This event will underscore CooperVision's role as a leader in the industry, reflecting its dedication to enhancing patient outcomes through evidence-based practices.
One of the notable studies being highlighted at the congress is an investigator-initiated paper that examines the transition of young adults from single vision lenses to dual-focus MiSight® 1 day lenses aimed at myopia control. Early findings indicate that patients report similar levels of vision quality and comfort within just six months of switching to these innovative lenses. Additionally, CooperVision showcases research into modern spherical lens designs, such as MyDay®, Biofinity®, and Biofinity Energys®, demonstrating their effectiveness in meeting the needs of both novice and experienced wearers, particularly when it comes to comfort and overall performance.
The congress will also delve into multifocal contact lenses, with three key studies emphasizing proactive fitting strategies for early presbyopic patients. These studies reveal high satisfaction rates among users who transition from hydrogel multifocal lenses to silicone hydrogel materials. Through this research, CooperVision aims to empower eye care professionals with the knowledge and tools necessary to better support patients entering contact lens wear, particularly as presbyopia becomes more prevalent with age. The NCC serves as a vital platform that brings together thousands of eye care professionals from around the world, further solidifying CooperVision’s influence in the field.
In addition to its participation in the NCC, Cooper Companies continues to receive mixed ratings from analysts, reflecting a spectrum of opinions regarding the company’s market strategies and future prospects. This analysis highlights the complexities of the medical device sector, where Cooper Companies operates primarily through its CooperVision and CooperSurgical divisions.
The company has also reported strong first-quarter earnings, surpassing analyst expectations, showcasing its robust operational trends. With an optimistic outlook for the next quarter, Cooper Companies' focus on innovative product offerings and market strategies positions it well to adapt and thrive within a competitive industry landscape.